Business Context and Reporting Period
This Form 8-K, dated August 11, 2026, reports on the special meeting of stockholders held by Apogee Therapeutics, Inc. (APGE). The filing details the results of votes regarding a proposed merger with Andor LLC, a wholly-owned subsidiary of AbbVie Inc., under which Apogee would become an indirect wholly-owned subsidiary of AbbVie.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and the outcome of the stockholder vote.
Material Changes and Voting Results
At the special meeting, 46,526,253 shares (approximately 74.87% of outstanding voting stock) were present. The results for the proposals were as follows:
- Proposal 1 (Merger Proposal): Approved. Stockholders voted 46,508,107 For, 3,885 Against, and 14,261 Abstentions. This approval satisfies a closing condition for the merger.
- Proposal 2 (Compensation Proposal): Not Approved. Stockholders voted 19,323,605 For, 27,123,259 Against, and 79,389 Abstentions. This vote was non-binding and advisory; its rejection does not prevent the merger from closing.
- Proposal 3 (Adjournment Proposal): Not voted upon as the Merger Proposal was approved.
Additionally, all current directors of Apogee have indicated their intention to resign effective at the time of the Merger. These resignations are not due to any disagreement regarding operations or policies.
Guidance, Outlook, and Risks
The filing confirms that the Merger Agreement was entered into on June 22, 2026. The approval of the Merger Proposal by stockholders is a key condition for consummation. The filing does not provide specific forward-looking guidance, risk factors, or contingencies beyond the standard conditions of the merger agreement.
Key Facts for Investor Verification
- Verify the final closing date of the merger with AbbVie following the stockholder approval.
- Confirm the specific terms of the merger consideration (cash or stock) for Apogee shareholders as detailed in the Definitive Proxy Statement.
- Monitor the resignation of the current board of directors and the appointment of new directors post-merger.
- Note that while the executive compensation related to the merger was rejected by shareholders, the merger itself remains on track as the vote was non-binding.